NNNN

20-F/A - Anbio Biotechnology (0001982708) (Filer)

3 - Anbio Biotechnology (0001982708) (Issuer)

3 - Anbio Biotechnology (0001982708) (Issuer)

3 - Anbio Biotechnology (0001982708) (Issuer)

3 - Anbio Biotechnology (0001982708) (Issuer)

3 - Anbio Biotechnology (0001982708) (Issuer)

20-F - Anbio Biotechnology (0001982708) (Filer)

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ:NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026. Anbio's CEO is scheduled to participate in a fireside chat and will have the opportunity to share the Company's previously disclosed business updates, strategic initiatives, and product development with the investor community. Anbio's participation in the conference reflects the Company's continued engagement with the investment community and supports its c

6-K - Anbio Biotechnology (0001982708) (Filer)

6-K - Anbio Biotechnology (0001982708) (Filer)

6-K - Anbio Biotechnology (0001982708) (Filer)

6-K - Anbio Biotechnology (0001982708) (Filer)

FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical. The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio's infectious disease diag

BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok. These events reflect Anbio's strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics. As healthcare systems around the world seek faster, more accurate, and decentralized testing solutions, Anbio is well-positioned to meet this demand through a diversified

20-F - Anbio Biotechnology (0001982708) (Filer)

6-K - Anbio Biotechnology (0001982708) (Filer)

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the "Company" or "Anbio"), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the "Offering") of 1,600,000 Class A ordinary shares (the "Class A Ordinary Shares") at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol "NNNN." The Company received aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts a